Benelux Cancer Therapeutics Market Report (2021-2031) by Scope, Segmentation, Dynamics, and Competitive Analysis

The cancer therapeutics market size is expected to reach US$ 14,840.87 million by 2031 from US$ 6,505.11 million in 2024. The market is estimated to record a CAGR of 12.62% from 2025 to 2031.

Executive Summary and Benelux Cancer Therapeutics Market Analysis:

Governments in the Benelux countries, alongside the European Union, provide substantial funding for cancer research and drug development. Initiatives such as Horizon Europe help foster innovation, enabling the rapid development and availability of novel cancer therapies.

Moreover, the Benelux region is home to a thriving pharmaceutical and biotech industry, with major global companies having a significant presence. Companies such as Johnson & Johnson, Acerta Pharma, and OncoDNA are actively involved in cancer drug development and clinical trials, further boosting the availability of novel cancer therapeutics in the region.

Benelux Cancer Therapeutics Market Segmentation Analysis:

Key segments that contributed to the derivation of the cancer therapeutics market analysis are therapy type, indication, and distribution channel.

By therapy type, the cancer therapeutics market is segmented into chemotherapy, targeted therapy, radiation therapy, hormone therapy, and other therapy types. The chemotherapy segment dominated the market in 2024. In terms of indications, the market is segmented into blood cancer, lung cancer, breast cancer, colorectum cancer, prostate cancer, stomach cancer, cervical cancer, liver and intrahepatic bile duct cancer, thyroid cancer, and other indications. The lung cancer segment held the largest share of the market in 2024. By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online stores. The hospital pharmacies segment held the largest share of the market in 2024.

Benelux Cancer Therapeutics Market Outlook

According to the Spanish Network of Cancer Registries, ~11,734 breast cancer cases were diagnosed in November 2022 in Belgium. Breast cancer was responsible for 2,362 deaths in the country in the said year. The increasing cancer incidence heightens the demand for cancer therapeutics in the country.

Additionally, there has been a significant increase in research and development for more effective and personalized cancer treatments. The Benelux region is known for its high level of investment in healthcare and biotechnology research. In Netherlands, Cancer therapeutics is a dynamic and rapidly evolving sector, driven by advancements in research, technology, and a robust healthcare system. The Dutch Cancer Society funds research and supports initiatives aimed at improving cancer care and outcomes. In September 2024, the Dutch Research Council (NWO) provided US$ 27.8 million (25 million euros) to address the ever-increasing challenges in cancer patient care. The number of cancer patients was expected to rise from 800,000 in 2022 to 1.4 million in 2031.

Benelux Cancer Therapeutics Market Country Insights

Based on region, the Benelux cancer therapeutics market is further segmented into the Belgium, the Netherlands, and Luxembourg. The Belgium held the largest share in 2024.

Belgium is home to numerous research collaborations, particularly in to fight against cancer. In April 2023, DeuterOncology, a Liège-based biotech company, was successfully awarded the Win4Company grant by Service Public de Wallonie (SPW) Recherche. This clinical-stage drug development company received US$ 0.53 million (0.47 million EUR) to establish a partnership with Radiomics, another Liège-based biotech, to combine their expertise in order to improve cancer therapy through the development and validation of an AI-based imaging biomarker as a potential companion diagnostic for a novel best-in-class deuterated MET kinase inhibitor (DO-2). The development of such novel biomarkers would allow the company to optimize and personalized cancer therapies. The grant brought together the expertise of two Belgian biotech companies for identifying subsets of lung cancer patients with MET gene alterations.

Benelux Cancer Therapeutics Market Company Profiles

Johnson & Johnson; AstraZeneca; GlaxoSmithKline BV; Modra Pharmaceuticals B.V; Telix Pharmaceuticals Limited; Sirius Medical; Gilead Sciences; LIXTE Biotechnology Holdings, Inc; Serb Pharmaceuticals; and iTeos Therapeutics are among the key players operating in the market. These companies are engaged in collaborative drug development to bring novel therapeutics for cancer in the market, aiming to stay ahead on competitive edge.

Benelux Cancer Therapeutics Market Research Methodology:

The following methodology has been followed for the collection and analysis of data presented in this report:

Secondary Research

The research process begins with comprehensive secondary research, utilizing both internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

Company websites, annual reports, financial statements, broker analyses, and investor presentations Industry trade journals and other relevant publications Government documents, statistical databases, and market reports News articles, press releases, and webcasts specific to companies operating in the marketNote:All financial data included in the Company Profiles section has been standardized to US$. For companies reporting in other currencies, figures have been converted to US$ using the relevant exchange rates for the corresponding year.

Primary Research

Business Market Insights conducts a significant number of primary interviews each year with industry stakeholders and experts to validate and analyze the data and gain valuable insights. These research interviews are designed to:

Refine findings from secondary research Enhance the expertise and market understanding of the analysis team Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects Primary research is conducted via email interactions and telephone interviews with industry experts across various markets, categories, segments, and sub-segments in different regions. Participants typically include:

Industry stakeholders:

Vice Presidents, business development managers, market intelligence managers, and national sales managers External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise Key Sources Referred:

Netherlands Cancer Institute (NKI) European Society for Medical Oncology OECD Health Database Global Cancer Observatory